{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:50Z","timestamp":1790516150752,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bulcan.2021.03.011","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T06:10:43Z","timestamp":1621491043000},"page":"771-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Leuc\u00e9mie \u00e0 tricholeucocytes\u00a0: quelles sont les meilleures options th\u00e9rapeutiques pour les patients en rechute ou r\u00e9fractaires\u00a0?"],"prefix":"10.1016","volume":"108","author":[{"given":"Xavier","family":"Troussard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5967-8225","authenticated-orcid":false,"given":"Elsa","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Paillassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.03.011_bib0260","doi-asserted-by":"crossref","first-page":"2","DOI":"10.18103\/mra.v8i10.2259","article-title":"Epidemiology of hairy cell leukemia and HCL-like disorders","volume":"8","author":"Troussard","year":"2020","journal-title":"Med Res Arch"},{"key":"10.1016\/j.bulcan.2021.03.011_bib0265","first-page":"100236","article-title":"A population-based study of hairy cell leukemia over a period of 20\u00a0years","volume":"25","author":"Wiber","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.bulcan.2021.03.011_bib0270","series-title":"WHO classification of tumours of haermatopoietic and lymphoid tissues (Revised 4th edition)","author":"Swerdlow","year":"2017"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2021.03.011_bib0275","first-page":"57","article-title":"The immunophenotype of hairy cell leukemia (HCL)","volume":"14","author":"Matutes","year":"1994","journal-title":"Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.bulcan.2021.03.011_bib0280","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1521-6926(02)00086-5","article-title":"The variant form of hairy-cell leukaemia","volume":"16","author":"Matutes","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2010.05.003","article-title":"Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment","volume":"37","author":"Robak","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.011_bib0295","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2007-07-098848","article-title":"Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?","volume":"111","author":"Traverse-Glehen","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0300","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1\u00a0mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.bulcan.2021.03.011_bib0305","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2016.160192","article-title":"Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3\u00a0and MYD88\u00a0mutations in splenic diffuse red pulp small B-cell lymphoma","volume":"102","author":"Jallades","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.011_bib0310","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.bulcan.2021.03.011_bib0320","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM198704023161401","article-title":"Remissions in hairy-cell leukemia with pentostatin (2\u2019-deoxycoformycin)","volume":"316","author":"Spiers","year":"1987","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.bulcan.2021.03.011_bib0325","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.leu.2402784","article-title":"Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238\u00a0patients","volume":"17","author":"Maloisel","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bulcan.2021.03.011_bib0335","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bjh.12908","article-title":"Long-term follow-up and second malignancies in 487\u00a0patients with hairy cell leukaemia","volume":"166","author":"Cornet","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.011_bib0340","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-020-0328-z","article-title":"Analysis of a cohort of 279\u00a0patients with hairy-cell leukemia (HCL): 10\u00a0years of follow-up","volume":"10","author":"Paillassa","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.011_bib0345","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"issue":"15","key":"10.1016\/j.bulcan.2021.03.011_bib0350","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/bloodadvances.2020002160","article-title":"Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial","volume":"4","author":"Benz","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0355","first-page":"001","article-title":"Cladribine in first line and relapsed hairy cell leukemia and the hairy cell leukemia variant","volume":"3","author":"Van Hoef","year":"2019","journal-title":"Int J Blood Dis Dis"},{"key":"10.1016\/j.bulcan.2021.03.011_bib0360","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hon.975","article-title":"Hairy cell leukaemia: biological and clinical overview from immunogenetic insights","volume":"29","author":"Forconi","year":"2011","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2021.03.011_bib0365","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/j.clml.2020.04.005","article-title":"Prognostic Value of Baseline Serum Lactate Dehydrogenase Level in Patients With Hairy Cell Leukemia","volume":"20","author":"Maral","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.bulcan.2021.03.011_bib0370","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bulcan.2021.03.011_bib0375","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","article-title":"Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation","volume":"119","author":"Xi","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2021.03.011_bib0380","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2021.03.011_bib0385","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.25653","article-title":"Hairy cell leukemia: 2020\u00a0update on diagnosis, risk stratification, and treatment","volume":"94","author":"Maitre","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.03.011_bib0390","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11864-020-00732-0","article-title":"Biology and Treatment of Hairy Cell Leukemia","volume":"21","author":"Paillassa","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2021.03.011_bib0395","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2005-11-4590","article-title":"Eradication of minimal residual disease in hairy cell leukemia","volume":"107","author":"Ravandi","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bulcan.2021.03.011_bib0400","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2011-04-351502","article-title":"Phase 2\u00a0study of cladribine followed by rituximab in patients with hairy cell leukemia","volume":"118","author":"Ravandi","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.011_bib0405","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.bulcan.2021.03.011_bib0410","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized phase II study of first-Line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia","volume":"38","author":"Chihara","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2021.03.011_bib0415","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1182\/blood-2018-04-843128","article-title":"MRD in HCL: does it matter?","volume":"131","author":"Ravandi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0420","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12839","article-title":"Peripheral blood 8\u00a0colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients","volume":"166","author":"Garnache Ottou","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.03.011_bib0425","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.14900","article-title":"Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?","volume":"183","author":"Ortiz-Maldonado","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.bulcan.2021.03.011_bib0430","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1200\/JCO.1995.13.10.2677","article-title":"Optimal treatment for untreated patients with hairy cell leukemia?","volume":"13","author":"Troussard","year":"1995","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2021.03.011_bib0435","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.V83.10.2931.2931","article-title":"Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment","volume":"83","author":"Kampmeier","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2021.03.011_bib0440","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-019-0201-0","article-title":"Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients","volume":"9","author":"Zheng","year":"2019","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.bulcan.2021.03.011_bib0445","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1\u00a0results and long-term follow-up","volume":"131","author":"Kreitman","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2021.03.011_bib0450","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.bulcan.2021.03.011_bib0455","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bulcan.2021.03.011_bib0460","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2021.03.011_bib0465","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/s41375-019-0646-y","article-title":"BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials","volume":"34","author":"Liebers","year":"2020","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bulcan.2021.03.011_bib0470","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bulcan.2021.03.011_bib0475","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1172\/JCI76539","article-title":"BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia","volume":"124","author":"Yaktapour","year":"2014","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2021.03.011_bib0480","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2018-99-113135","article-title":"Treatment with combination of dabrafenib and trametinib in patients with recurrent\/refractory BRAF V600E-mutated hairy cell leukemia","volume":"132","author":"Kreitman","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2021.03.011_bib0485","first-page":"99","article-title":"Hairy cell leukemia. An update on a cohort of 93\u00a0patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment","volume":"14","author":"Troussard","year":"1994","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.bulcan.2021.03.011_bib0490","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"Bendamustine and rituximab in relapsed and refractory hairy cell leukemia","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.bulcan.2021.03.011_bib0495","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1182\/blood.V128.22.1215.1215","article-title":"Efficacy and safety of the Bruton Tyrosine Kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1\u00a0results of a phase 2\u00a0study","volume":"128","author":"Jones","year":"2016","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2021.03.011_bib0500","first-page":"409","article-title":"The chemotherapy-free combination of vemurafenivb and rituximab produces deep and durable responses in relapsed or refractory hairy cell leukemia (HCL) patients","volume":"130","author":"Tiacci","year":"2017","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.bulcan.2021.03.011_bib0505","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hon.2594","article-title":"New treatment options in hairy cell leukemia with focus on BRAF inhibitors","volume":"37","author":"Falini","year":"2019","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2021.03.011_bib0255","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/ajh.25264","article-title":"Biclonal IGHV-4-34\u00a0hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax","volume":"93","author":"Jain","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:34:40Z","timestamp":1757792080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":51,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0007455121001661"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.03.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leuc\u00e9mie \u00e0 tricholeucocytes\u00a0: quelles sont les meilleures options th\u00e9rapeutiques pour les patients en rechute ou r\u00e9fractaires\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}